The 2022 PSOGI International Consensus on HIPEC Regimens for Peritoneal Malignancies: Epithelial Ovarian Cancer
- PMID: 37561343
- DOI: 10.1245/s10434-023-13932-3
The 2022 PSOGI International Consensus on HIPEC Regimens for Peritoneal Malignancies: Epithelial Ovarian Cancer
Abstract
Background and aim: We report the results of an international consensus on hyperthermic intraperitoneal chemotherapy (HIPEC) regimens for epithelial ovarian cancer (EOC) performed with the following goals: To define the indications for HIPEC To identify the most suitable HIPEC regimens for each indication in EOC To identify areas of future research on HIPEC To provide recommendations for some aspects of perioperative care for HIPEC METHODS: The Delphi technique was used with two rounds of voting. There were three categories of questions: evidence-based recommendations [using the Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) system with the patient, intervention, comparator, and outcome (PICO) method], an opinion survey, and research recommendations.
Results: Seventy-three (67.5%) of 108 invited experts responded in round I, and 68 (62.9%) in round II. Consensus was achieved for 34/38 (94.7%) questions. However, a strong positive consensus that would lead to inclusion in routine care was reached for only 6/38 (15.7%) questions. HIPEC in addition to interval cytoreductive surgery (CRS) received a strong positive recommendation that merits inclusion in routine care. Single-agent cisplatin was the only drug recommended for routine care, and OVHIPEC-1 was the most preferred regimen. The panel recommended performing HIPEC for a minimum of 60 min with a recommended minimum intraabdominal temperature of 41°C. Nephroprotection with sodium thiosulfate should be used for cisplatin HIPEC.
Conclusions: The results of this consensus should guide clinical decisions on indications of HIPEC and the choice and various parameters of HIPEC regimens and could fill current knowledge gaps. These outcomes should be the basis for designing future clinical trials on HIPEC in EOC.
Keywords: Advanced ovarian cancer; Epithelial ovarian cancer; HIPEC; Interval cytoreductive surgery; Recurrent ovarian cancer.
© 2023. Society of Surgical Oncology.
Comment in
-
ASO Author Reflections: Which HIPEC Regimens Should be Used in Patients with Epithelial Ovarian Cancer? In the Clinic and in Randomized Trials.Ann Surg Oncol. 2023 Dec;30(13):8166-8167. doi: 10.1245/s10434-023-13981-8. Epub 2023 Jul 21. Ann Surg Oncol. 2023. PMID: 37477748 No abstract available.
References
-
- Bhatt A, Glehen O. Hyperthermic intraperitoneal chemotherapy in the treatment armamentarium of epithelial ovarian cancer: time to end the dichotomy. Visc Med. 2022;38(2):109–19. https://doi.org/10.1159/000521239 . (Epub 2022). - DOI - PubMed - PMC
-
- Helderman RFCPA, Löke DR, Tanis PJ, Tuynman JB, Ceelen W, de Hingh IH, van der Speeten K, Franken NAP, Oei AL, Kok HP, Crezee J. Preclinical in vivo-models to investigate HIPEC; current methodologies and challenges. Cancers (Basel). 2021;13(14):3430. https://doi.org/10.3390/cancers13143430 . - DOI - PubMed - PMC
-
- Bhatt A, Van Der Speeten K, Hubner M, Kusamura S, Glehen O. ASO Author reflections: standardizing HIPEC methodology and regimens: a prelude to the PSOGI expert consensus. Ann Surg Oncol. 2021;28(13):9114–5. https://doi.org/10.1245/s10434-021-10205-9 . (Epub 2021 Jun 4 PMID: 34089108). - DOI - PubMed
-
- Bhatt A, de Hingh I, Van Der Speeten K, Hubner M, Deraco M, Bakrin N, Villeneuve L, Kusamura S, Glehen O. HIPEC methodology and regimens: the need for an expert consensus. Ann Surg Oncol. 2021;28(13):9098–113. https://doi.org/10.1245/s10434-021-10193-w . (Epub 2021 Jun 17 PMID: 34142293). - DOI - PubMed
-
- Kusamura S, Bhatt A, Hubner M, Villeneuve L, Deraco M, Bakrin N, Van Der Speeten K, Glehen O. The PSOGI international consensus on HIPEC regimens for peritoneal malignancies: methodology. Ann Surg Oncol. 2023. https://doi.org/10.1245/s10434-022-12990-3 . - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
